Journal Watch · British Journal of Pharmacology · 2026
Peripheral targets for neuropathic pain.
The ongoing clinical trials are encouraging, with an expectation of not only new drugs for established targets but also new mechanistic options.
TL;DR
The ongoing clinical trials are encouraging, with an expectation of not only new drugs for established targets but also new mechanistic options.
Key findings
- For targets with approved drugs, the scope encompasses authorisation for other clinical indications, with subsequent emphasis on their mechanistic relevance to neuropathic pain.
- For targets without approved drugs but for which substances were or are currently tested in clinical trials, there is a focus on their progress.
- For the novel targets, the preclinical evidence for pain and in particular neuropathic pain is presented.
- The ongoing clinical trials are encouraging, with an expectation of not only new drugs for established targets but also new mechanistic options.
What they did
Results were classified as 'large targets', 'rising targets' and 'novel targets'. Ion channels were more prominent in the established targets compared with more recently addressed targets. The 15 top hits in the literature for each of the three categories are discussed.
Full abstract (original)
Background: Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with 'neuropathic pain' in PubMed overall and in the past 6 years was analysed.
What they did: Results were classified as 'large targets', 'rising targets' and 'novel targets'. Ion channels were more prominent in the established targets compared with more recently addressed targets. The 15 top hits in the literature for each of the three categories are discussed.
Results & conclusions: For targets with approved drugs, the scope encompasses authorisation for other clinical indications, with subsequent emphasis on their mechanistic relevance to neuropathic pain. For targets without approved drugs but for which substances were or are currently tested in clinical trials, there is a focus on their progress. For the novel targets, the preclinical evidence for pain and in particular neuropathic pain is presented. The ongoing clinical trials are encouraging, with an expectation of not only new drugs for established targets but also new mechanistic options.
Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70553 · PubMed 42394346.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking British Journal of Pharmacology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this British Journal of Pharmacology study find?
The ongoing clinical trials are encouraging, with an expectation of not only new drugs for established targets but also new mechanistic options.
What type of study is this?
It is a review / perspective, published in British Journal of Pharmacology in 2026. Results were classified as 'large targets', 'rising targets' and 'novel targets'.
Where can I read the original paper?
The original is at the publisher via DOI 10.1111/bph.70553. PubMed ID: 42394346. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/peripheral-targets-for-neuropathic-pain-h70553/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides